Clinical trials for Breast cancer

198 currently recruiting clinical trials
Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
HER2 Negative HR Positive Locally Advanced Metastatic 2 3 or more Targeted therapy Hormone therapy
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer #NCT06330064 #2023-509632-26-00
HER2 Low HR Positive Locally Advanced Metastatic 2 3 or more Targeted therapy Hormone therapy
Systemic Treatment-Naive
10 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant BRAF 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant EGFR MET NTRK-1/2/3 RET ROS-1 Other mutation 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer #NCT05800275
HER2 Positive Metastatic 1 2 3 or more
10 recruiting sites
UNICANCER
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer #NCT05732831 #2022-502645-99-00
Locally Advanced Metastatic Metastatic Castration-resistant MTAP 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Tango Therapeutics
Phase 2 Breast cancer #NCT05296746 #2023-508827-10-00
HER2 Negative HR Positive Localized None Systemic Treatment-Naive Systemic Treatment-Naive
25 recruiting sites
Novartis